Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

A new target for the treatment of schizophrenia

Published on: 04/09/2014 Reading time: 1 min
Illustration

The Biotechnology & Biotherapy team, created by Dr. Jacques Mallet and presently directed by Dr. Philippe Ravassard, at Paris Brain Institute, in collaboration with the Pole of Therapeutic Innovation in Neuropsychiatry at the Servier Research Institute, has highlighted a new therapeutic target for the treatment of schizophrenia. It is about a new receptor called “Gpr88” – a protein present on cell surface – and localized exclusively in the brain. Authors show that local inactivation of “Gpr88” normalizes some behaviors altered in a model of schizophrenia. These behaviors are refractory to the current therapies utilized in humans. This work, conducted by Manuela Ingallinesi for her Ph.D. thesis under the scientific direction of Dr. Rolando Meloni, constitutes an important breakthrough in the validation of Gpr88 as a novel therapeutic target as well as an innovative experimental approach for the treatment of schizophrenia. This study has been published August 26th 2014 in Molecular Psychiatry one of the leading journals in psychiatric research.

Schizophrenia, characterized by “positive”, “negative” and “cognitive” symptoms, is a serious and handicapping mental illness affecting about 1% of the population. The current therapies are essentially based on neuroleptics that allow for managing “positive” symptoms such as delusions and hallucinations, as well as “negative” symptoms such as blunted affect and lack of emotions, but are less effective against “cognitive” deficits, characterized by disorganized thinking. Moreover, up to one third of the patients do not respond to these therapies. Therefore, new therapeutic targets are actively sought for improving the treatment of schizophrenia symptoms, particularly cognitive deficits.

 

“Gpr88” is a receptor (a protein present on cell surface) with an unknown role that is expressed almost exclusively in the Striatum, a brain structure deeply implicated in neuropsychiatric diseases. The interest of the Biotechnology and Biotherapy team for Gpr88 stems from the work of Drs Meloni and Mallet in psychiatric genetic showing that the gene coding for Gpr88 is associated as a risk factor with schizophrenia. To address the biological basis of this association, Dr. Meloni and his collaborators have assessed the role of Gpr88 using a rat model of schizophrenia.

 

The researchers show that local inactivation of this protein in the Nucleus Accumbens (a brain structure, localized in the ventral part of the Striatum, whose function is deeply altered in the course of schizophrenia) significantly reduces the behavioral alterations associated to the schizophrenia model. Notably, a normal behavior in a social cognition test is reestablished by the inactivation of Gpr88 in the Nucleus Accumbens.

 

These results, which have just been published in the scientific review Molecular Psychiatry, show that Gpr88 is a novel potential therapeutic target of great interest for the treatment of schizophrenia. It is for the Institut du Cerveau - ICM and its researchers a new hope for the development of novel treatments that may take care of the cognitive deficits refractory to the currently used drugs.

 

Illustration
In the center: coronal section of rat’s brain showing (red box) the region of the Nucleus Accumbens (NAcc) in the Striatum (STR) where the protein Gpr88 is inhibited – Ctx: cerebral cortex. In the left: magnification of the red box area with a fluorescent microscope showing in green the region of the Nucleus Accumbens where Gpr88 is inhibited and in red the remaining Striatum still expressing Gpr88. In the right: localization of the regions mentioned in a see- through reproduction of the human brain.

 

Sources

Ingallinesi et al., Local inactivation of Gpr88 in the Nucleus Accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine, Molecular Psychiatry (online publication, 26 August 2014)

Our news on the subject

Le cortex moteur
Origin of Lance-Adams Syndrome Finally Elucidated
First described 60 years ago, chronic myoclonus following cerebral anoxia is now known as Lance-Adams syndrome. This is a severe disorder whose mechanisms were, until now, poorly understood. Geoffroy Vellieux, Vincent Navarro, and their colleagues at...
06.16.2025 Research, science & health
Tiré de New Theory of Colours de Mary Gartside, 1808
Aphantasia Might Be Linked to Alterations in Brain Connectivity
Thanks to 7T fMRI, researchers from Paris Brain Institute and NeuroSpin, the CEA's neuroimaging centre, are exploring the neural substrate of visual imagery at very high resolution for the first time. Their results, publiés [i] in Cortex, pave the...
06.06.2025 Research, science & health
Le développement du cerveau a une part d’aléatoire
The stochastic aspect of brain development
Although every person’s personality is the result of genetic and environmental factors, these are not the only factors at play. Bassem Hassan and his team at Paris Brain Institute have discovered that, in fruit flies (drosophila), individuality also...
05.12.2025 Research, science & health
Analyse MERSCOPE
New treatment pathways for brain malformation-linked focal epilepsy?
A study by Stéphanie Baulac’s team has revealed somatic mutations in different cell types in patients with type 2 focal cortical dysplasia. This disease causes drug-resistant epileptic seizures, for which the main treatment option is currently...
05.12.2025 Research, science & health
Un iceberg
The ICEBERG cohort, 10 years of collective scientific and medical mobilization
The ICEBERG cohort, initiated 10 years ago, is interested in studying factors predictive of the onset and progression of Parkinson’s disease.
05.15.2025 Research, science & health
La huntingtine est une protéine indispensable au développement embryonnaire, à la formation et au maintien du tissu cérébral.
Huntington's Disease: The Energy Hypothesis Gets Traction
Huntington's disease, a rare hereditary neurological disorder, is associated with an energy deficit that precedes the onset of symptoms and is closely linked to their progression. At Paris Brain Institute, Fanny Mochel and her colleagues are testing...
02.11.2025 Research, science & health
See all our news